MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia

Advances in molecular biology, polymerase chain reaction (PCR), and next-generation sequencing (NGS) have transformed the concept of minimal residual disease (MRD) from a philosophical idea into a measurable reality. Acute promyelocytic leukemia (APL) leads the way in this transformation, initially...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-09, Vol.16 (18), p.3208
Main Authors: Kegyes, David, Thiagarajan, Praveena S, Ghiaur, Gabriel
Format: Article
Language:English
Subjects:
Acute promyeloid leukemia
Bone marrow
Chemotherapy
Decision making
Disease
Flow cytometry
Leukemia
Medical prognosis
Methods
Microenvironments
Minimal residual disease
Morphology
Mutation
Next-generation sequencing
Polymerase chain reaction
Promyeloid leukemia
Remission
Remission (Medicine)
Review
Stem cells
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Advances in molecular biology, polymerase chain reaction (PCR), and next-generation sequencing (NGS) have transformed the concept of minimal residual disease (MRD) from a philosophical idea into a measurable reality. Acute promyelocytic leukemia (APL) leads the way in this transformation, initially using PCR to detect MRD in patients in remission, and more recently, aiming to eliminate it entirely with modern treatment strategies. Along the way, we have gained valuable insights that, when applied to other forms of acute leukemia, hold the potential to significantly improve the outcomes of these challenging diseases. In this review, we explore the current use of MRD in the management of acute leukemia and delve into the biological processes that contribute to MRD persistence, including its overlap with leukemia stem cells and the role of the bone marrow microenvironment.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16183208